Abwiz Bio Inc, founded in 2012, is dedicated to advancing commercial biological research and development. The company specializes in the production of high-impact monoclonal antibodies, leveraging phage display technology and rabbit immunization to achieve exceptional specificity, affinity, and functionality. Abwiz Bio serves the needs of discovery research, lead identification for therapeutics, and diagnostics development, positioning itself as a leader in the biotechnology sector.
Abwiz Bio has made significant strides in the biotechnology field by delivering custom monoclonal antibodies that meet the rigorous demands of modern research and development. Their innovative approach has earned them a reputation for excellence in antibody specificity and functionality. The company's impact is evident in its ability to speed up the development process for therapeutic and diagnostic applications, making it a valuable partner for researchers and developers worldwide.
